Search all of our news releases here.

Generic filters

Try these: Jeff GalvinHIVFDAAmerican Gene Technologies

American Gene Technologies Appoints Dr. Marcus A. Conant as Special Advisor to the CEO

Oct 1, 2021

Dr. Conant, one of the first HIV/AIDS treatment pioneers, strengthens AGT’s capacity to progress toward a functional cure October 01, 2021 13:25 ET | Source:  American Gene Technologies American Gene Technologies (AGT) announces the appointment of Dr. Marcus A. Conant, a leading dermatologist in the U.S. and… [Read More]

American Gene Technologies HIV Cure Clinical Trial Shows Additional Progress with No Serious Adverse Events (SAEs)

Sep 23, 2021

American Gene Technologies (AGT), a clinical-stage biotechnology company, announced that the independent Data Safety and Monitoring Board (DSMB) in charge of the trial safety found no serious adverse events (SAEs) from the treatment for the second patient and voted unanimously to allow AGT’s HIV cure program to… [Read More]

American Gene Technologies Appoints Dr. Robert R. Redfield as Special Advisor to the CEO

Sep 15, 2021

Dr. Redfield’s expertise in virology strengthens AGT’s capacity to develop innovative HIV treatments. American Gene Technologies (AGT) announces the appointment of Dr. Robert R. Redfield, former director of the Centers for Disease Control and Prevention (CDC) and co-founder of the Institute for Human Virology, as… [Read More]

HIV Cure Program Releases Initial Clinical Trial Data

Jul 16, 2021

ROCKVILLE, MD, July 15, 2021 /Globe Newswire/ — American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the… [Read More]

First Infusion Press Release

AGT Announces Progress with HIV Cure Program, Phase 1 Clinical Trial

May 27, 2021

ROCKVILLE, MD, May 27, 2021 /PR Newswire/ — American Gene Technologies (AGT), a clinical-stage biotechnology company, announced treatment of the first participant in its Phase I clinical trial to evaluate safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore… [Read More]

LGBT+ investment firm Gaingels joins American Gene Technologies’ mission to cure HIV, and other serious human diseases

LGBT+ Investment Firm Gaingels Joins American Gene Technologies’ Mission to Cure HIV, and Other Serious Human Diseases

Apr 14, 2021

ROCKVILLE, Md., Apr. 15, 2021 /PRNewswire/ – American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical… [Read More]

American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV

Nov 10, 2020

ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated… [Read More]

American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

Oct 8, 2020

ROCKVILLE, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s… [Read More]

FDA Approves American Gene Technologies (AGT) To Move Forward With Phase 1 Clinical Trial Of HIV Cure Program

Aug 11, 2020

ROCKVILLE, Md., Aug. 11, 2020 /PRNewswire/ — American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program. AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area,… [Read More]

Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure

Aug 3, 2020

ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), an internationally recognized advanced gene and cell therapy company in Rockville, MD, today announced a coauthored article by scientists from AGT and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National… [Read More]

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media